Approved for Maintenance treatment of COPD, Maintenance treatment of asthma in patients aged 18 years and older, Reduction of COPD exacerbations. Triple therapy combining fluticasone furoate (ICS), umeclidinium (LAMA), and vilanterol (LABA). Addresses inflammation, cholinergic bronchoconstriction, and beta-2 mediated bronchodilation… Side effects, costs, interactions, manufacturer, and generic…
Loading full data from Know Your Drugs Institute…